US market remains the model as template issuance takes shape

◆ AFT's Antoine Deruennes says 'clear message' showed demand for 30 year ◆ Speedy execution before US employment data ◆ Green OAT syndication next

◆ Refi deal came as issuer prepares IPO ◆ Deal extends the insurer's tier two curve by 10 years ◆ 'Strong bid' for Iberian FIG credit, says rival banker

◆ Portuguese utility firm powers up EuGB curve ◆ Sub-benchmark trade's book proves sticky ◆ Deal lands through fair value

◆ €500m 4NC3 EuGB deal priced inside fair value ◆ Greenium helps tighten spreads amid strong demand ◆ Landmark trade cements bank's ESG leadership, says treasurer

◆ Austrian lender completes its tightest unsecured debt since the start of war in Ukraine… ◆ …as BPM achieves its lowest ever senior spread ◆ High attrition function of premium and outright spread

When loans' LTVs hit 80%, Bitcoin stakes are liquidated in seconds

London continues to benefit from metal price volatility

Latest issue rides on coattails of big tech investment spree

Deal is backed by three data centers in Virginia, Illinois and Atlanta

Only one of Canada's big five banks has yet to publicly support new defence bank initiative

Hyperscaler earnings could become a crucial date for issuance funding calendars

The yield was ultra high but Congo had little room to manoeuvre

Benin showed Islamic issuance is a viable market for sub-Saharan African sovereigns

Sovereign left little, if anything, on the table for investors

Observers have questioned why the country is issuing debt at this price

Deal will bring fourth major multilateral development bank to the market

The bank's regular appearances in primary markets stopped after Russia invaded Ukraine

No one wins playing the blame game

Craig Coben examines whether it is true that no good deed goes unpunished

Investors and bankers grapple with 24% fall in Bitcoin since deal was rated

Anis Lahlou is chief investment officer at Aperture Investors in London. He believes that asset managers must change the way they charge fees to their investors, by only charging them for market-beating performance.

BioNTech, the German biopharmaceuticals company, is selling 5.5m American Depositary Receipts (ADRs) on the Nasdaq through a share sale and a rights issue. The company, which is working with Pfizer to develop a vaccine for Covid-19, is the latest issuer to hit the market in a wave of biotech ECM issuance — but buyers are being warned against being too eager, reports Sam Kerr.

The International Finance Facility for Immunisation (IFFIm) was set up in 2006 to provide funding to Gavi, the Vaccine Alliance, itself a public/private sector partnership, to expedite the vaccination of children in the poorest countries against endemic infectious diseases. Doris Herrera-Pol, IFFIm board member and former director of global capital markets at the World Bank, spoke to GlobalCapital about the role the capital markets can play in the development and deployment of a Covid-19 vaccine.